The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes

Haematologica

Volumn 91, Issue 6, 2006, Pages 750-756

  De Witte, Theo ^a   Brand, Ronald ^b   Van Biezen, Anja ^c   Delforge, Michel ^d   Biersack, Harold ^e   Or, Reuven ^f   Meloni, Giovanna ^g   Bandini, Beppe ^h   Sierra, Jorge ⁱ   Kröger, Nicolaus ^j   Gratwohl, Alois ^k   Niederwieser, Dietger ^l  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c Chronic Leukemia Working Party Registry Leiden ^*  (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^k UNIVERSITY HOSPITAL BASEL   (Switzerland)

^l UNIVERSITY HOSPITAL LEIPZIG   (Germany)

more..

Author keywords

Autologous hematopoietic stem cell transplantation; Bone marrow stem cells; Mobilized peripheral blood stem cells; Myelodysplastic syndromes; Secondary acute myeloid leukemia

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; INFANT; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; NEWBORN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RELAPSE; RISK FACTOR; STEM CELL; SURVIVAL;

ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 33745745266     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1984;59:425-33.
2. Bennett JM, Catovsky D, Daniel MD, Flandrin G, Galton DAG, Gralnick, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
3. Greenberg P, Cox C, LeBeau MM, Fénaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
4. O'Donnell MR, Nademanee A, Snyder DS, Schmidt GM, Parker PM, Bierman PJ, et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 1987;5:1822-6.
5. Longmore G, Guinan EC, Weinstein HJ, Gelber RD, Rappaport JM, Antin JH. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphobiastic leukaemia. J Clin Oncol 1990;8:1707-14.
6. De Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J. et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 1990;74:151-5.
7. Sutton L, Chastang C, Ribaud P, Jouet JP, Kuentz M, Attal M, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients. Blood 1996;88:358-65.
8. Nevill TJ, Shepherd JD, Reece DE, Barnett MJ, Nantel SH, Klingeman HG, et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 1992;10:445-50.
9. Anderson JE, Appelbaum FR, Fisher LD, Schoch G, Shulman H, Anasetti C, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993;82:677-81.
10. Anderson JE, Appelbaum FR, Schoch G, Shulman H, Anasetti C, Bensinger WI, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996;87:51-8.
11. Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, et al. On behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Bone Marrow Transplant 1998;21:255-60.
12. De Witte T, Muus P, De Pauw B, Haanen C. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukaemia. Cancer 1990;66:831-7.
13. Fénaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991;77:497-501.
14. De Witte T, Suciu S, Peetermans M, Fénaux P, Strijckmans P, Hayat M, et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myelogenous leukaemia following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment of Cancer (EORTC-LCG). Leukemia 1995;9:1805-11.
15. Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rasset SM, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of myelodysplastic syndromes and acute myefoid leukaemia. Br J Haematol 1997;99:939-44.
16. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukaemia [AML]) on outcome of AML-type chemotherapy. Blood 1997;90:2969-77.
17. Laporte JP, Isnard F, Lesage S, Fenaux P, Douay L, Lopez M, et al. Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study. Leukemia 1993;7:2030-3.
18. De Witte T, Van Biezen A, Hermans J, Labopin M, Runde V, Or R, et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia following MDS. Blood 1997;90:3853-7.
19. Wattel E, Solary E, Leleu X, Dreyfus F, Brion A, Jouet JP, et al. Groupe Français des Myélodysplasies (GFM) and Groupe Ouest-Est d'étude des Leucémies aiguës myéloïdes (GOELAM). A prospective study of autologous bone marrow or peripheral stem cell transplantation in myelodysplastic syndromes. Leukemia 1999;13:524-9.
20. Gratwohl A, Baldomero H, Schmid O, Horisberger B, Bargetzi M, Urbano-Ispizua A, et al. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplant 2005;36:575-90.
21. De Witte T, Brand R, van Biezen A, Delforge M, Runde V, Or R, et al. Peripheral stem cells are the preferred source of stem cells for autologous stem cell transplantation (ASCT) of young patients with MDS or AML following MDS: an analysis of the Chronic Leukaemia Working Party of the European Blood and Marrow Transplantation Group (EBMT) (#3525) Blood 2001;97:848a[abstract].
22. De Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report an behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000;110:620-30.
23. Demuynck H, Delforge M, Verhoef GE, Zachee P, Vandenberghe P, Vandenberghe H, et al. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 1996;92:351-9.
24. Oosterveld M, Suciu S, Rodts P, Muus P, de Witte T. Peripheral blood stem cell mobilization after chemotherapy in patients with high-risk myelodysplastic syndrome. Leukemia 1999;23:584.
25. Carella AM, Dejana A, Lerma E, Podesta M, Benvenuto F, Chimirri F, et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol 1996;95:127-30.
26. Delforge M, Demuynck H, Vandenberghe P, Verhoef G, Zachee P. Duppeen VV, et al. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 1995;86:3660-7.
27. Benito AI, Bryant E, Loken M, Sale GE, Nash RA, Gass MJ, et al. NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human progenitors. Leuk Res 2003;27:425-36.
28. Anderson JE, Gooley TA, Schoch G, Anasetti C, Bensinger WI, Clift RA, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997;89:2578-85.
29. Mattijsen V, Schattenberg A, Schaap N, Preijers F, de Witte T. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone Marrow Transplant 1997;19:791-4.
30. de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukaemia following MDS. Blood 2001;98:2326-31.
31. Oosterveld M, Suciu S, Verhoef G, Labar B, Belhabri A, Aul C, et al. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia 2003;17:859-68.
32. Oosterveld M, Muus P, Suciu S, Koller C, Verhoef G, Labar B, et al. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 2002;16:1615-21.
33. Ljungman P, De Witte T, Verdonck L, Gahrton G, Freycon F, Gravett P, et al. Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukemia Working Party prospective analysis from HLA-typing. Br J Haematol 1993;84:61-6.
34. Kearing S, De Witte T, Suciu S, Willemze R, Hayat M, Labar B, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukemia Cooperative Group and GIMEMA. Br J Haematol 1998;102:1344-53.